Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
September 20, Wednesday 2017 6:33 PM       

       HEADLINES: Keralashabdam Managing Editor Dr B A Rajakrishnan passes away                                              Son beats father, drives him out of house                                              State school festival in January only                                              Principal held for sexual harassment                                              Charge sheet against Dileep to be filed on Oct 7                                              How India, China perform would fundamentally shape the world: Rahul                                              Heavy rains in Mumbai, flight services hit                                              Toll surges to 248 in powerful Mexico quake                                              India win four medals in Asian Martial Arts Games                                              Bairstow to open for England in 1st Windies ODI                                              After Ramkumar's decisive defeat, Yuki gets consolation win                                              Players choose Amarjit to lead India in FIFA U-17 WC                                              After Dhoni, Tendulkar now a biopic on woman cricketer Jhulan                                              Kaumudi Facebook
       SCI&TECH Next Article: Threat of asteroid impact looming over Earth: experts  
       New drug to treat blood cancer developed
 
         Posted on :19:38:19 Jun 10, 2017
   
A A
       Last edited on:19:38:19 Jun 10, 2017
         Tags: New drug, blood cancer
 
NEW YORK: A new drug for blood cancer that may provide better treatment alone or combined with chemotherapy has been developed by a team led by an Indian-origin scientist.
 
Acute lymphoblastic leukemia or ALL can affect both children and adults.
 
Scientists have found up to 30 per cent of adult ALL patients have what is called a Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. The ALL cancer cells containing the Philadelphia chromosome are addicted to repairing DNA.
 
"Repairing DNA may sound like a good thing when you are talking about healthy cells. But in this case it is a bad thing. When you treat these leukemia cells with chemotherapy, you want DNA damage to accumulate so the cancer cells will die," said Srividya Bhaskara, a post doctoral at University of Utah in the US.
 
"However, because the Philadelphia chromosome continually causes repair, these cells do not retain enough DNA damage to die. Essentially they resist any kind of drug you use on them. So we had to find a new way to overcome this DNA repair addiction," she said.
 
Researchers found that the Philadelphia chromosome promotes repair through numerous proteins. But putting together a cocktail of drugs to inhibit them all would likely be too toxic and affect normal cells.
 
Bhaskara focused on two specific proteins she found were directly involved in DNA repair, called histone deacetylases (HDAC) 1 and 2. She then collaborated with a company to make a drug that inhibits HDAC1,2 activity.
 
After a comprehensive analysis of how the drug worked, Bhaskara tested the HDAC1,2 inhibitor in patient samples and mice and saw encouraging results, either alone or in combination with a chemotherapy drug called doxorubicin.
 
Doxorubicin is one of the components of the chemotherapy cocktail regimen currently used for Philadelphia chromosome-positive ALL patients.
 
Researchers found that the drugs broke down the central hub of DNA repair, and the HDAC1,2 inhibitor actually reduced different repair protein functions.
 
"The treated mice did not get sick from the drug, and we did not see any apparent toxic side-effects in them. And when the drug was combined with a low concentration of doxorubicin, it had additional therapeutic benefits," Bhaskara said.
 
"We actually show in the patient-derived mouse models that using the combination of drugs, or HDAC1,2 inhibitor alone, is sufficient to decrease the leukemia load," she said.
 
Leukemia is a white blood cell disease where the body produces too many white and not enough red blood cells.
 
When the mice in this study were treated with the HDAC1,2 inhibitor or the HDAC1,2/doxorubicin combination, their bone marrow started turning from pale to red, indicating the white blood cells were being replaced with red blood cells, researchers said.
 
"We completely nailed down how the HDAC1,2 inhibitor affects DNA repair. This is so important, not just for this cancer, but any cancer that is repair-addicted. We know there is a specific type of lymphoma that is also repair-addicted," Bhaskara said.
 
The study was published in the journal Leukemia.
A A
       SCI&TECH
Next Article: Threat of asteroid impact looming over Earth: experts
 
 
SCI&TECH HEADLINES
Astrophysicists make music from Saturn's moons, rings  
Rooter includes Kabbadi, F1 under one roof  
Orbiting supermassive black holes discovered for first time  
Theweightmonitor.com launches mobile app for easier access to one-stop weight management platform  
New drug to treat blood cancer developed  
Threat of asteroid impact looming over Earth: experts  
Hottest known planet in universe discovered  
Wireless, battery-less pacemaker developed  
'Manned missions to Moon, Mars may face medical emergencies'  
Ransomware threat: Centre activates mechanism to prevent ‘Wannacry’ cyber attack  
2 lakh hit by 'unprecedented' cyberhack in 150 nations:Europol  
foodpanda revamps mobile app; provides more options  
ixigo launches trains app for Apple iOS users  
Virtual humans may help doctors learn empathy: study  
Gamers, here are five games to watch out for  
Yahoo India homepage gets brand new look  
Spacecraft flies between Saturn and rings in historic 1st  
Google targets 'fake news,' offensive search suggestions  
Offensive WhatsApp posts can land group admin in jail  
Facebook for 'everyone' and not just high end: Zuckerberg  
Google Earth re-invented for new era  
NASA images show how India looks from space at night  
Signs of life detected below world's deepest point  
'iPhones assembly in Bengaluru by Apple in less than a month'  
Five astronauts assigned to future ISS mission: NASA  
 
Do you think Vellapally Natesan will join LDF, eventually?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy